2668.3000 85.40 (3.31%)
NSE Nov 09, 2026 15:31 PM
Volume: 1.5M
 

2668.30
3.31%
Motilal Oswal
Mankind’s domestic formulation (DF) business is witnessing a healthy revival, with Mar’26 growth at 11.5% YoY vs. IPM growth at 10.6% (1.1pp outperformance).
Mankind Pharma Ltd. is trading above all available SMAs
More from Mankind Pharma Ltd.
Recommended